Show simple item record

dc.rights.licenceAttribution-NonCommercial 4.0 International*
dc.contributor.authorRosenthal, Víctor Daniel
dc.contributor.authorMaki, Dennis George
dc.contributor.authorMehta, Yatin
dc.sourceAmerican Journal of Infection Control; Vol. 42 Núm. 9 (2014)spa
dc.titleInternational Nosocomial Infection Control Consortiu (INICC) report, data summary of 43 countries for 2007-2012. Device-associated modulespa
dc.subject.keywordHospital infectionspa
dc.subject.keywordNosocomial infectionspa
dc.subject.keywordHealth care-associated infectionspa
dc.subject.keywordDevice-associated infectionspa
dc.subject.keywordAntibiotic resistancespa
dc.subject.keywordVentilator-associated pneumoniaspa
dc.subject.keywordCatheter-associated urinary tract infectionspa
dc.subject.keywordCentral line-associated bloodstream infectionsspa
dc.subject.keywordBloodstream infectionspa
dc.subject.keywordUrinary tract infectionspa
dc.subject.keywordDeveloping countriesspa
dc.subject.keywordLimited resources countriesspa
dc.subject.keywordLow income countriesspa
dc.description.abstractenglishWe report the results of an International Nosocomial Infection Control Consortium (INICC) surveillance study from January 2007-December 2012 in 503 intensive care units (ICUs) in Latin America, Asia, Africa, and Europe. During the 6-year study using the Centers for Disease Control and Prevention’s (CDC) U.S. National Healthcare Safety Network (NHSN) definitions for device-associated health careeassociated infection (DA-HAI), we collected prospective data from 605,310 patients hospitalized in the INICC’s ICUs for an aggregate of 3,338,396 days. Although device utilization in the INICC’s ICUs was similar to that reported from ICUs in the U.S. in the CDC’s NHSN, rates of device-associated nosocomial infection were higher in the ICUs of the INICC hospitals: the pooled rate of central lineeassociated bloodstream infection in the INICC’s ICUs, 4.9 per 1,000 central line days, is nearly 5-fold higher than the 0.9 per 1,000 central line days reported from comparable U.S. ICUs. The overall rate of ventilator-associated pneumonia was also higher (16.8 vs 1.1 per 1,000 ventilator days) as was the rate of catheter-associated urinary tract infection (5.5 vs 1.3 per 1,000 catheter days). Frequencies of resistance of Pseudomonas isolates to amikacin (42.8% vs 10%) and imipenem (42.4% vs 26.1%) and Klebsiella pneumoniae isolates to ceftazidime (71.2% vs 28.8%) and imipenem (19.6% vs 12.8%) were also higher in the INICC’s ICUs compared with the ICUs of the CDC’s
dc.type.localArtículo de revistaspa
dc.contributor.corporatenamePontificia Universidad Javeriana. Facultad de Medicina. Departamento de Medicina Interna. Grupo de Investigación en Enfermedades Infecciosas HUSI - PUJ

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial 4.0 International
Except where otherwise noted, this item's license is described as Attribution-NonCommercial 4.0 International